ArticleCancer investigation2011

Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors.

David A Rizzieri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.